How States are Using the Law to Bring Drug Executives to Heel
Troutman Sanders partner Daniel Anziska was quoted in a Feb. 16 MedCity News article about price increases in the generic drug industry. With regards to a lawsuit filed by 20 states in December 2016 against six companies after a major antitrust investigation, Daniel told the reporter, “I think this is a new development. This is kind of a new permutation. It’s been going on a couple years, the investigation. But this is kind of what’s starting to trickle out of it.” He also explained that the majority of antitrust cases in the pharmaceutical industry have been pursued in accordance with the Hatch-Waxman Act, a law that promotes the development of generic drugs.